Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of BIIB033 study 215ON201 in acute optic neuritis
2015-003618-26Phase 2Completed
- Sponsor
- Biogen
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of opicinumab in optic neuritis (ON) (2 arms), sponsored by Biogen. Primary endpoint: Change in full-field visual evoked potential latency. Started Oct 2015; status: completed.
02
Drugs
opicinumab
03
Conditions
optic neuritis (ON)
Beyond the preview
Go deeper on 2015-003618-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003618-26.